US 12,083,097 B2
Dual TNFR1 antagonists and TNER2 agonists for use in renal diseases
Eva Steiness, Hellerup (DK); and Torben Frank Skarsfeldt, Vedbæk (DK)
Assigned to SERODUS AS, Oslo (NO)
Appl. No. 18/252,339
Filed by SERODUS AS, Oslo (NO)
PCT Filed Nov. 12, 2021, PCT No. PCT/EP2021/081482
§ 371(c)(1), (2) Date May 9, 2023,
PCT Pub. No. WO2022/101389, PCT Pub. Date May 19, 2022.
Claims priority of application No. 20207534 (EP), filed on Nov. 13, 2020.
Prior Publication US 2023/0414562 A1, Dec. 28, 2023
Int. Cl. A61K 31/357 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/357 (2013.01) [A61P 13/12 (2018.01)] 9 Claims
 
1. A method for the treatment of a population of patients suffering from a renal disease, wherein the population to be treated is characterized by having a serum level of sTNFR1 of >2.9 ng/ml and/or an ACR>300 mg/g, and wherein said method comprises administering a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Chemistry